Kane Biotech (CVE:KNE) Stock Price Up 28.6% – Still a Buy?

by · The Cerbat Gem

Kane Biotech Inc. (CVE:KNE – Get Free Report) shares rose 28.6% during trading on Saturday . The stock traded as high as C$0.05 and last traded at C$0.05. Approximately 1,505,028 shares changed hands during trading, an increase of 380% from the average daily volume of 313,629 shares. The stock had previously closed at C$0.04.

Kane Biotech Stock Performance

The stock has a fifty day simple moving average of C$0.04 and a two-hundred day simple moving average of C$0.04. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The stock has a market cap of C$7.53 million, a price-to-earnings ratio of -0.56 and a beta of 0.60.

About Kane Biotech

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.

Further Reading